You are here:

September 2011 references and further reading

COURAGE not followed by action

Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WS. Optimal medical therapy with or without PCI for stable coronary disease. New England Journal of Medicine 2007; 356:1503-16.

Borden WB, Redberg RF, Mushlin AI, Dai D, Kaltenbach LA, Spertus JA. Patterns and intensity of medical therapy in patients undergoing percutaneous coronary intervention. JAMA 2011; 305:1882-9.

Maron DJ, Boden WE, Weintraub WS, Calfas KJ, O’Rourke RA. Is optimal medical therapy as used in the COURAGE trial feasible for widespread use? Current Treatment Options in Cardiovascular Medicine 2011; 13:16-25.

Yla-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hoefer I, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgozoglu L. Stabilisation of atherosclerotic plaques. Position Paper of the European Society of Cardiology (ESC) Working Group on Atherosclerosis and Vascular Biology. Thrombosis and Haemostasis 2011; 106:1-19.

What to do when blood pressure resists control

Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011; 57:1076-80.

de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.

Dudenbostel T, Calhoun DA. Resistant hypertension, obstructive sleep apnoea and aldosterone. Journal of Human Hypertension 2011.

Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-26.

Peripheral artery disease often goes untreated

Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: national health and nutrition examination study, 1999 to 2004. Circulation 2011; 124:17-23.

Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM, Jr., White CJ, White J, White RA, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease. Journal of the American College of Cardiology 2006; 47:1239-312.

Abundance of fructose not good for liver, heart

Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nature Reviews of Gastroenterology and Hepatology 2010; 7:251-64.

Lustig RH. Fructose: metabolic, hedonic, and societal parallels with ethanol. Journal of the American Dietetic Association 2010; 110:1307-21.

Stanhope KL, Havel PJ. Fructose consumption: recent results and their potential implications. Annals of the New York Academy of Sciences 2010; 1190:15-24.

Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine 2010; 363:1341-50.

Johnson RK, Appel LJ, Brands M, Howard BV, Lefevre M, Lustig RH, Sacks F, Steffen LM, Wylie-Rosett J. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation 2009; 120:1011-20.

“Polypill” test raises questions

An international randomised placebo-controlled trial of a four-component combination pill (“polypill”) in people with raised cardiovascular risk. PLoS One 2011; 6:e19857.

Caution advised on Chantix use

FDA Drug Safety Communication. Chantix (varenicline) may increase the risk of certain cardiovascular adverse events in patients with cardiovascular disease. June 16, 2011.

Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ 2011. Published online, July 4, 2011

Another day in the sun for olive oil?

Samieri C, Feart C, Proust-Lima C, Peuchant E, Tzourio C, Stapf C, Berr C, Barberger-Gateau P. Olive oil consumption, plasma oleic acid, and stroke incidence: The Three-City Study. Neurology 2011. Published online, June 15, 2011.

Failing hearts linked to broken bones

Gerber Y, Melton LJ, 3rd, Weston SA, Roger VL. Association between myocardial infarction and fractures: an emerging phenomenon. Circulation 2011.

Gerber Y, Melton LJ, 3rd, Weston SA, Roger VL. Osteoporotic fractures and heart failure in the community. American Journal of Medicine 2011; 124:418-25.

Warensjo E, Byberg L, Melhus H, Gedeborg R, Mallmin H, Wolk A, Michaelsson K. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. BMJ 2011; 342:d1473.

Pause in CPR before shock reduces survival

Cheskes S, Schmicker RH, Christenson J, Salcido DD, Rea T, Powell J, Edelson DP, Sell R, May S, Menegazzi JJ, Van Ottingham L, Olsufka M, Pennington S, Simonini J, Berg RA, Stiell I, Idris A, Bigham B, Morrison L. Perishock pause: an independent predictor of survival from out-of-hospital shockable cardiac arrest. Circulation 2011; 124:58-66.

Sodium/potassium ratio important for health

Yang Q, Liu T, Kuklina EV, Flanders WD, Hong Y, Gillespie C, Chang M-H, Gwinn M, Dowling N, Khoury MJ, Hu FB. Sodium and potassium intake and mortality among US adults. Archives of Internal Medicine 2011; 171:1183-1191.

Posted by: Dr.Health

Back to Top